To assess the potential uptake of HIV pre-exposure prophylaxis (PrEP) products among female sex workers (FSWs) vulnerable to HIV infection, we examined the influence of product attributes on willingness to use products among 271 HIV-negative FSWs in Tijuana and Ciudad Juarez, Mexico (2016-2017). Via five-point Likert scale ratings, participants indicated their willingness to use hypothetical products with six attributes: formulation (pill, gel, liquid, or ring), frequency of use (daily, on-demand, or monthly), cost per use (10 or 200 pesos), effectiveness (40% or 80%), side effects (none or mild), and access point (healthcare clinic or non-governmental organization). Conjoint analysis was used to determine the impact of attributes on product ratings and identify preferred product attributes. Multinomial logistic regression was used to identify factors associated with formulation preferences. In both cities, formulation and frequency of use had the greatest impact on ratings. Participants in Ciudad Juarez indicated a strong preference for oral pills, whereas participants in Tijuana indicated roughly equal preferences for oral pills and vaginal gels. Monthly product use was preferred in both cities. Compared to preferring oral pills (38%), preferring vaginal gels (28%) was associated with practicing vaginal lubrication (adjusted odds ratio ¼ 2.08; 95% confidence interval: 1.07-4.04). Oral PrEP may be acceptable to many FSWs in Tijuana and Ciudad Juarez; however, continued development of behaviorallycongruent vaginal PrEP products may also facilitate uptake and ensure sufficient coverage.
Introduction
Daily oral tenofovir-emtricitabine (TDF/FTC) is an efficacious HIV prevention strategy, [1] [2] [3] [4] recommended for use as pre-exposure prophylaxis (PrEP) by individuals at substantial risk of HIV infection. 5 Monthly use of dapivirine-containing vaginal rings as PrEP provides moderate protection against HIV infection and is currently under regulatory review. 6, 7 In addition, other systemic (e.g. injectable and implantable) and topical (e.g. gels, douches, films, and suppositories applied vaginally or rectally) antiretroviral-based PrEP products are in development. Although one trial documented moderate protection associated with on-demand (i.e. before and after sex) use of tenofovir-containing vaginal gel, 8 in other trials neither daily nor on-demand gel use were protective. 9, 10 However, across all PrEP trials, greater efficacy was observed in the context of more consistent product use. [1] [2] [3] [4] [6] [7] [8] Recent evidence that vaginal microbiota associated with bacterial vaginosis (BV) may metabolize tenofovir, and effectively reduce the efficacy of tenofovir-containing vaginal PrEP products, reinforces the need to maintain high levels of adherence, especially in the presence of BV. 11, 12 Outside the United States (US), daily oral PrEP has not been widely implemented. 13 Yet, despite the US Food and Drug Administration's approval of Truvada (TDF/FTC) for daily oral use as PrEP in 2012, uptake remains low among women in the US.
14 Implementation of sustained-release, dapivirine-containing vaginal PrEP rings could reduce barriers to uptake associated with oral PrEP's daily use requirements and potential systemic side effects. However, the continued development of non-systemic, short-acting behaviorally-congruent vaginal PrEP products may also facilitate uptake and adherence among women. Female sex workers (FSWs) are particularly vulnerable to HIV infection with their odds of infection estimated to be 13.5 times those among reproductive-aged women. 15 However, PrEP efficacy trials have largely excluded FSWs. 16 Although intravaginal practices, including washing and lubrication, vary across regions and cultures, 17, 18 FSWs often perform intravaginal practices. [19] [20] [21] [22] [23] [24] Consistent use of behaviorally-congruent vaginal PrEP gels or douches may be less challenging for FSWs, particularly if they can be integrated into their existing practices.
Several studies have documented high acceptability of hypothetical PrEP products formulated as oral pills, [25] [26] [27] vaginal gels, 28, 29 and vaginal rings 27 among FSWs globally. Conjoint analysis (CJA) is a marketbased research technique used to identify consumers' preferred product attributes and examine the impact of those attributes on consumers' willingness to use a product. [30] [31] [32] Galea et al. employed CJA to explore preferred oral PrEP product attributes among key populations, including FSWs, in Peru, and identified preferences for low-cost, highly efficacious products without side effects. 33 Eisingerich et al. used CJA to examine PrEP product attribute preferences within an international sample of FSWs and found that the route of administration was most important to participants, with injections preferred to oral pills. 34 Few studies conducted with FSWs have simultaneously examined preferences between oral and vaginal (gel, liquid, ring) PrEP formulations.
In the present study, Proyecto PrEParado (Project PrEPared), we employed CJA to examine the impact of product attributes on willingness to use oral and vaginal PrEP products and identify preferred product attributes among FSWs in Tijuana and Ciudad Juarez, two northern Mexico border cities. HIV prevalence in Mexico is highest among key populations, including transgender women (17.4%), men who have sex with men (17.3%), sex workers (7.0%), and people who inject drugs (2.5%). 35 Along the Mexico-US border, HIV prevalence among FSWs (6%) 36 and FSWs who inject drugs (12%) 37 is roughly 15 and 30 times that among reproductive-aged women nationally (0.4%), 35 respectively. Similar to FSWs globally, 38 HIV risk among FSWs along the Mexico-US border is influenced by structural factors that limit their capacity to negotiate condom use with clients, which underscores their need for user-controlled HIV prevention methods, such as PrEP. Daily oral PrEP demonstration projects are currently underway with key populations in Mexico City and are expected to inform the implementation of oral PrEP nationally. 13 Findings from the present study could expand our understanding of the potential uptake of oral PrEP and inform the continued development and future implementation of other PrEP products acceptable to FSWs in the Mexico-US border region and other similar low-income settings.
Methods

Study population
Proyecto PrEParado was conducted from 2016 to 2017 among FSWs in Tijuana and Ciudad Juarez participating in a randomized controlled trial evaluating a text message-based behavioral HIV prevention intervention. Trial recruitment was conducted by outreach workers at known sex work locations (e.g. bars, street corners). Eligible women were cisgender female, !18 years-old, HIV-negative, reported exchanging sex for money, drugs, or goods (past month), reported condom-unprotected vaginal/anal sex with a client (past month), agreed to accept free treatment if they tested STI-positive, and owned a cell phone. Participants provided written informed consent and institutional review boards at the University of California, San Diego, Xochicalco University in Tijuana, and SADEC-FEMAP in Ciudad Juarez approved the study. [NGO] ). Because these attributes could be combined into 192 (4 Â 3Â2 Â 2Â2 Â 2) distinct hypothetical products, we used specialized algorithms to identify efficient fractional-factorial designs. 48 The smallest fractional-factorial design that was both balanced (i.e. attribute levels occur equally within each attribute) and orthogonal (i.e. all main effects can be estimated and are uncorrelated) consisted of 24 products. Since asking participants to consider 24 products would be too burdensome, we selected an efficient (Defficiency ¼ 95.25), balanced, and nearly orthogonal (correlation between formulation and cost, effectiveness, side effects, and access point ¼ 0.33; all other attribute pairs were uncorrelated) fractional-factorial design consisting of 12 products ( Table 2) . Some of the hypothetical products contain attribute combinations that may not be feasible (i.e. daily or ondemand use of vaginal rings, monthly use of oral pills, vaginal gels, or vaginal liquids). However, the theoretical framework underlying CJA posits that consumers' willingness to use a product can be decomposed into the specific effects of each product attribute. 31, 32 The goal of CJA is not to identify attribute combinations most acceptable to consumers, but rather to understand trade-offs made by consumers with respect to product attributes when presented with products with a range of attributes. Including hypothetical PrEP products with potentially infeasible attribute combinations does not compromise the ability of our CJA to identify preferred product attributes or determine the influence of those attributes on participants' willingness to use PrEP products. [30] [31] [32] Prior to initiating the CJA exercise, interviewers followed a script to inform participants of PrEP's efficacy, potential side effects, and the need for routine HIV/STI testing and clinical monitoring while using PrEP. The script also defined the attributes under investigation and provided examples to facilitate comprehension. Participants were also shown pictures of potential product formulations. Next, interviewers presented 12 cards to participants in random order, with each card containing a different hypothetical product. Participants were then asked to (1) rank each product from 1 (most likely to use) to 12 (least likely to use) and (2) rate products by indicating their willingness to use products ("Would you be willing to use the PrEP product presented on the card to protect yourself against HIV?") via five-point Likert scale responses (no, definitely not; probably not; unsure; probably; yes, definitely). Overall, interviewers indicated that participants comprehended the differences between the products presented and completed the CJA exercise with little difficulty in under 10 minutes. 
Study procedures
HIV/STI testing procedures
Statistical analysis
We conducted a CJA to identify preferred levels within product attributes and determine the impact of those attributes on participants' willingness to use PrEP products. First, five-point Likert scale product ratings reflecting participants' willingness to use products were converted to a 100-point scale (i.e. 1 recoded as 0, 2 recoded as 25, etc.). Next, separate analysis of variance (ANOVA) models were fit for each participant to model product ratings as a function of the six attributes to obtain participant-specific part-worth utilities (PWUs) and importance values (IVs). 48 PWUs are equivalent to ANOVA parameter estimates, sum to zero for each attribute, and reflect relative preferences for levels within attributes. A positive PWU for an attribute level indicates a relative preference for that level, while a negative PWU for an attribute level indicates a relative aversion to that level. IVs were calculated for each attribute by dividing the range of PWUs for an attribute by the sum of PWU ranges for all attributes multiplied by 100. IVs sum to 100 across attributes and reflect the relative influence of each attribute on product ratings. Attributes with higher IVs have a greater impact on participants' willingness to use a product. PWUs and IVs were then averaged across participants by study site. Because familiarity with similar products, existing vaginal practices, and motivations for performing those practices might impact formulation preferences, we examined whether non-condom contraceptive use, vaginal symptoms, pain during vaginal sex, STIs, and vaginal washing and lubrication practices were associated with formulation preferences using separate multinomial logistic regression models adjusting for intervention group assignment, study site, socio-demographics, substance use, and sex work characteristics. In the multinomial logistic regression models, we examined interaction terms between covariates and study site, but because none were statistically significant results are not stratified by study site. Analyses were performed using SAS 9.4 (SAS Institute, Inc., Cary, NC).
Analysis sample
The parent trial enrolled 602 FSWs (302 Tijuana; 300 Ciudad Juarez). Participants who returned for their STI test results and completed the Proyecto PrEParado supplemental survey were considered for inclusion in our analysis. Sample sizes of $300 are recommended for CJA. 30 Proyecto PrEParado was initiated at the same time as and six months after the initiation of the parent trial in Ciudad Juarez and Tijuana, respectively, and continued until $150 participants completed the survey in each city. Seventy-three percent (163/224) and 50% (150/300) of those enrolled in Tijuana and Ciudad Juarez, respectively, after the initiation of Proyecto PrEParado completed the survey. Participants who completed the survey were more likely to report vaginal symptoms (33% vs. 23%; p-value ¼ 0.02) and condom use during a greater proportion of vaginal sex acts with clients (0.6 vs. 0.5; p-value ¼ 0.002), and were less likely to report an average monthly income !3500 pesos (70% vs. 84%; p-value ¼ 0.0003). No other statistically significant differences were observed. To ensure the relevance of baseline data to our analysis, we excluded 18 participants who completed the survey more than three months post-baseline. Because CJA cannot be applied to data from participants who rate all products equally, we excluded five participants with no variability in their ratings. Finally, we excluded 19 participants with ANOVA R 2 values <0.7, which indicates poor model fit suggesting they may not have taken the CJA exercise seriously. 48 Our analysis sample consisted of 271 FSWs (127 Tijuana; 144 Ciudad Juarez).
Results
Participants had a median age of 38 years (interquartile range [IQR]¼30-46) ( Table 1) . A higher proportion of participants in Ciudad Juarez reported non-condom contraceptive use (81% vs. 15%; p-value < 0.0001), while a higher proportion in Tijuana reported vaginal symptoms (43% vs. 24%; p-value ¼ 0.001), pain during vaginal sex (17% vs. 4%; p-value ¼ 0.001), tested STI-positive (26% vs. 9%; p-value ¼ 0.0002), and reported practicing vaginal lubrication (67% vs. 47%; p-value ¼ 0.001) and washing (58% vs. 22%; p-value < 0.0001). A greater proportion of participants in Tijuana who reported practicing vaginal lubrication did so daily (55% vs. 33%; p-value ¼ 0.01), while a similar proportion of participants reported daily vaginal washing in Tijuana (33%) and Ciudad Juarez (26%) (p-value ¼ 0.64).
Most participants (94% Tijuana; 99% Ciudad Juarez) reported that they would probably/definitely use their highest ranked product (rank ¼ 1), whereas few participants (15% Tijuana; 1% Ciudad Juarez) reported that they would probably/definitely use their lowest ranked product (rank ¼ 12 (Figure 1 PWU¼-6.80, SD ¼ 21.75) indicated a strong aversion to vaginal rings. Participants in both cities indicated strong preferences for products that are 80% effective (vs. 40%), moderate preferences for products that cost 10 pesos per use (vs. 200) and can be used monthly (vs. daily or on-demand), and slight preferences for products that can be accessed at healthcare clinics (vs. NGOs), but no obvious preferences (mean PWUs < 0.50) regarding side effects. Among participants whose PWUs indicated a preference for one product formulation (N ¼ 268), 38%, 28%, 18%, and 17% preferred pills, gels, rings, and liquids, respectively. Compared to preferring pills, preferring gels was associated with reporting pain during vaginal sex (adjusted odds ratio [AOR]¼3.51, 95% confidence interval [CI]: 1.13-10.84) and vaginal lubrication practices (AOR ¼ 2.08, 95% CI: 1.07-4.04) ( Table 3) .
Discussion
We used CJA to investigate willingness to use hypothetical oral and vaginal PrEP products among FSWs in Tijuana and Ciudad Juarez, Mexico. Consistent with previous research suggesting high PrEP acceptability among FSWs, [25] [26] [27] [28] [29] nearly all participants were interested in using their highest-ranked PrEP product. Our findings build on previous research by providing insight on FSWs' preferred PrEP product attributes that may affect uptake of oral PrEP and have implications for the continued development of vaginal PrEP rings, gels, and douches.
Product formulation had the greatest influence on overall product ratings among participants in both Tijuana and Ciudad Juarez suggesting that formulation preferences may drive future PrEP use within this population. Preferences for oral PrEP relative to vaginal products among participants in Ciudad Juarez and some participants in Tijuana indicate that uptake of oral PrEP products, which are currently being brought to scale globally, may be high among FSWs in the Mexico-US border region. This finding is consistent with preferences among women participating in a cross-over trial in the US whose preferences were largely explained by the widespread availability and use of medications formulated as oral pills in the US. 41 Given the proximity of Tijuana and Ciudad Juarez to the US, preferences for oral pills within our sample may similarly be explained by FSWs' familiarity with oral pill medications in the Mexico-US border region. 41, 49, 50 Preferences for PrEP formulated as vaginal gels among participants in Tijuana may be explained by a desire for more pleasurable sexual encounters as suggested by the relationship between preferring PrEP formulated as vaginal gels and reporting pain during vaginal sex and vaginal lubrication practices, both of which were reported by more Tijuana participants. As such, some FSWs may recognize vaginal PrEP gels as a behaviorally congruent HIV prevention strategy that can be easily incorporated into their existing vaginal practices to enhance lubrication and comfort during sex, which is consistent with research suggesting a relationship between increased sexual pleasure and vaginal PrEP gel acceptability. 51, 52 The relatively strong aversion to vaginal PrEP rings may reflect infrequent use of contraceptive vaginal rings by women in Mexico. Nevertheless, no single product formulation was overwhelmingly preferred within our sample, with each formulation preferred by 17% to 38% of participants. Thus, our findings indicate a need for multiple PrEP product formulations, including behaviorally-congruent vaginal PrEP gels and douches, to facilitate uptake and ensure sufficient PrEP coverage among FSWs. In Tijuana and Ciudad Juarez, frequency of use had the second greatest influence on PrEP product ratings. Participants preferred monthly product use to daily and on-demand use, which they may have perceived as less burdensome and easier to adhere to. 33, 49 Of the formulations considered, only vaginal rings are being developed for monthly use. As such, uptake of daily oral PrEP may be low among FSWs who prefer products that can be used monthly. Given the aversion toward vaginal rings in our sample, future research should examine the acceptability of other sustainedrelease products, which require less frequent use. Although access point and side effects had little impact on product ratings within our sample, the systemic nature of other sustained-release products (e.g. injectable and implantable), which will require regular clinic visits and may have side effects that cannot be as easily reversed as those associated with non-systemic, short-acting products, may enhance the acceptability of more frequent PrEP product use. More specifically, because 31% and 45% of participants who reported vaginal washing and lubrication in the past month, respectively, did so at least daily, more frequent dosing may be acceptable for nonsystemic, short-acting behaviorally-congruent vaginal PrEP gels or douches that can be integrated into FSWs' existing practices.
While efficacy and cost influenced PrEP product ratings, they were not as important to FSWs in our sample as they were to participants from Peruvian key populations in Galea et al.'s study. 33 While the influence of product attributes (i.e. IVs) can be overestimated for attributes with more levels, IVs and PWUs reflect the influence of attributes and attribute preference, respectively, relative to the other attributes considered, as such findings across CJAs considering different attributes are not comparable. 31 Thus, these discrepancies are likely explained by varying attributes in each study. The relationship between each covariate of interest and preferred PrEP product formulation (outcome) was examined in a separate multinomial logistic regression model adjusted for intervention group assignment, study site, socio-demographics (age, education, average monthly income), substance use (illicit drug use in the past month, hazardous alcohol consumption), and sex work characteristics (number of clients in the past month, percent of vaginal sex acts with clients in the past month that were condom-protected). Our study has several limitations. First, non-random sampling may limit the generalizability of our findings. Second, due to social desirability bias, participants may have overstated their interest in using the PrEP products presented. Third, although participants were informed of the potential side effects of PrEP use and the need for regular clinical and laboratory monitoring for their occurrence, no distinction was made between systemic, non-systemic, long-acting, and short-acting products with respect to the nature of side effects or the necessary frequency of monitoring for those side effects. As such, our findings do not account for the potential impact of clinical and laboratory monitoring on willingness to use PrEP products. Moreover, characteristics of PrEP delivery programs (e.g. location and frequency of HIV/STI testing) could also affect PrEP product uptake. To the extent that this monitoring and these characteristics are unacceptable relative to other product attributes, our findings may overestimate FSWs' willingness to use oral and vaginal PrEP products. Fourth, while CJA is useful for assessing preferred product attributes, qualitative research is needed to better understand attribute preferences. Fifth, while it is possible that FSWs could use vaginal PrEP products rectally, questions related to topical products (gel, liquid, ring) only referred to their vaginal use. Research examining this possibility is needed as it has implications for the development of multi-compartment (i.e. vagina and rectum) PrEP products. Finally, uptake may differ from hypothetical willingness to use PrEP.
In one of the first studies to examine willingness to use oral and vaginal PrEP products among FSWs in Mexico, we identified a strong interest in the use of these user-controlled HIV prevention strategies. Our findings provide important information regarding PrEP product attribute preferences and their relative impact on potential product uptake. Implementation of various PrEP product formulations, including behaviorally-congruent vaginal gels and douches, may enhance future PrEP uptake and adherence, and ultimately reduce the burden of HIV among FSWs.
